



(11) **EP 2 012 125 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**23.01.2013 Bulletin 2013/04**

(51) Int Cl.:  
**G01N 33/58** (2006.01) **G01N 33/02** (2006.01)  
**C07K 7/06** (2006.01) **C07K 7/08** (2006.01)

(21) Application number: **08166032.6**

(22) Date of filing: **30.04.2001**

(54) **Molecular modification assays**

Anordnungen zur Molekularmodifizierung

Analyses de modification moléculaire

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

(30) Priority: **28.04.2000 US 200594 P**  
**19.06.2000 US 596444**  
**08.08.2000 US 223642 P**  
**17.10.2000 US 241032 P**  
**27.04.2001 US 844655**  
**09.06.2000 PCT/US00/16025**

(43) Date of publication of application:  
**07.01.2009 Bulletin 2009/02**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**01303960.7 / 1 156 329**

(73) Proprietor: **Molecular Devices, LLC**  
**Sunnyvale, CA 94089-1136 (US)**

(72) Inventors:  
• **Huang, Wei**  
**Cupertino, CA 95014 (US)**  
• **Sportsman, J. Richard**  
**Encinitas, CA 92024 (US)**  
• **Terpetschnig, Ewald A.**  
**Urbana, IL 61801 (US)**  
• **Hoekstra, Merl E.**  
**Monroe, WA 98272 (US)**

(74) Representative: **Harrison Goddard Foote**  
**Belgrave Hall**  
**Belgrave Street**  
**Leeds**  
**LS2 8DD (GB)**

(56) References cited:  
**WO-A-00/47693 WO-A-00/75167**  
**WO-A-00/75662 WO-A-00/75664**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 012 125 B1**

**Description****Field of the Invention**

**[0001]** The invention relates to assays for molecular modifications. More particularly, the invention relates to assays for detecting molecular modifications such as phosphate modifications and the presence and/or activity of enzymes and other agents involved in facilitating or otherwise regulating such modifications.

**Background of the Invention**

**[0002]** The physiological modification of molecules and supramolecular assemblies plays a major role in the structure and regulation of biological systems. These modifications may include phosphorylation, cyclization, glycosylation, acylation, and/or sulfation, among others, and the modified molecules may include polypeptides, nucleic acids, and/or lipids, among others. The importance of modifications is particularly evident in the cell-signaling pathway, in which extracellular and intracellular substances related by phosphate modifications such as phosphorylation and cyclization influence the position, nature, and activity of cells.

**[0003]** Figure 1 is a schematic view of a representative cell-signaling pathway 100. Here, signaling cells 102 produce signal substances 104a,b that interact with target cells 106 to effect a response in the target cells. These responses may be short term, such as glycogen breakdown or muscle contraction, among others. These responses also may be long term, such as growth, differentiation, reproduction, and/or apoptosis, among others. Generally, these responses are brought about by increasing, decreasing, and/or maintaining enzyme activity in the target cells.

**[0004]** Signaling cells 102 are cells capable of producing a signal (substance) that can effect a specific response in another (target) cell. The signaling cells may be components of an endocrine, paracrine, or nervous system. The endocrine system is an organism-wide control system that regulates body function using hormones released by endocrine organs into the bloodstream. The endocrine organs include the pituitary gland, thyroid gland, parathyroid glands, adrenal glands, thymus gland, pineal body, pancreas, ovaries, testes, and kidneys. The paracrine system is a local control system that regulates nearby cells using local mediators released into the extracellular medium. The nervous system is a specialized control system that regulates specific cells using electrical impulses and neurotransmitters.

**[0005]** Signal substances 104a,b are substances through which a signaling cell may communicate with target cells, evoking a specific response. Signal substances may act as hormones, local mediators, and/or neurotransmitters, among others. Signal substances may take the form of proteins, small peptides, amino acids, nucleotides, steroids (e.g., cortisol, steroid sex hormones, vitamin D), retinoids, fatty acid derivatives, and dissolved gases (e.g., nitric oxide (NO) and carbon monoxide (CO)), among others.

**[0006]** Target cells 106 are cells capable of responding to a specific signal substance produced by a signaling cell. The ability to respond may depend on the cell and on the signal substance. For example, the signal substance thyroxine from the thyroid gland may evoke a response in nearly all cells, whereas the signal substance progesterone from the ovary may evoke a response only in specific cells in the lining of the uterus. The target response may include kinase activity, GTP binding, and/or cyclic nucleotide production.

**[0007]** The ability of a cell to respond to a given signal substance generally is determined by whether the cell includes a receptor for the signal substance. Here, a receptor is any molecule or supramolecular assembly capable of specifically binding a signal substance and initiating a response in a target cell. Representative receptors include cell-surface receptors 110 located on the surface of the target cell and intracellular receptors 112 located within the cytosol 114 or nucleus 116 of the target cell.

**[0008]** The nature of the response initiated by binding of a signal substance is determined by the intracellular machinery to which the receptor is operatively coupled. For example, binding of the neurotransmitter acetylcholine to identical receptors in heart muscle cells and secretory cells causes muscle relaxation in the heart muscle cells and secretion in the secretory cells, due to differences in the associated intracellular machinery.

**[0009]** The remainder of this section examines (1) the receptor mechanisms that cells use to bind signal substances and to communicate this binding to the cell interior, (2) the intracellular pathways that cells use for regulation, (3) the effects of errors in cell-signaling pathways, and (4) selected shortcomings of current cell-signaling assays.

**1. Receptor Mechanisms**

**[0010]** Target cells generally have receptors capable of specifically binding specific signal substances, including cell-surface receptors and/or intracellular receptors, as described above. Cell-surface receptors are more common and include (A) G-protein-linked receptors, (B) enzyme-linked receptors, and (C) ion-channel-linked receptors. These receptors typically bind large and/or water-soluble signal substances, such as many peptide hormones. Intracellular receptors are less common and include (A) guanylyl cyclase and (B) ligand-activated gene regulatory proteins. These

receptors typically bind small and/or water-insoluble signal substances, such as steroid hormones, thyroid hormones, retinoids, vitamin D, and NO.

**[0011]** Figure 2 is a schematic view of a representative G-protein-linked cell-surface receptor mechanism 130 that includes a receptor protein 132, a G-protein 134, and a target protein 136. These proteins may be positioned on or within the plasma membrane 138 of a target cell. In use, a specific signal substance 140 binds to a signal-substance binding site 142 on the extracellular side 144 of the receptor protein and thereby creates, exposes, or otherwise activates (\*) a G-protein binding site 146 on the intracellular side 148 of the receptor protein. The G-protein then binds to the G-protein binding site on the receptor protein and thereby creates, exposes, or otherwise activates (\*) a target-protein binding site 150 on the G-protein. The G-protein then dissociates from the receptor protein, binds (via the target-protein binding site) to the target protein, and activates (\*) the target protein. Activation and deactivation of the G-protein may involve binding of a guanosine triphosphate (GTP) molecule and dephosphorylation of the GTP molecule, respectively. The receptor protein may belong to a large superfamily of homologous; seven-pass transmembrane proteins. These seven-pass proteins consist of a single polypeptide chain that crosses the membrane seven times, with an extracellular signal-substance binding portion and an intracellular catalytic portion. The G-protein may be trimeric, consisting of three polypeptide chains-- $\alpha$ ,  $\beta$ , and  $\gamma$ --that associate and dissociate during signaling. The target protein may consist of an enzyme or ion channel, among others. In particular, the target protein may be an enzyme that modulates the presence or activity of second messengers within the cell. These second messengers (also known as intracellular messengers or intracellular mediators) may bind allosterically to specific cellular proteins to alter their conformation and hence their activity. These second messengers include adenosine 3,5'-cyclic monophosphate (cAMP) and calcium ( $\text{Ca}^{2+}$ ).

**[0012]** In the cAMP pathway, the target protein may be adenylyl cyclase (also known as adenylate cyclase), and the G-protein may be a stimulatory G-protein ( $\text{G}_s$ ) that activates the adenylyl cyclase to make cAMP, or an inhibitory G-protein ( $\text{G}_i$ ) that inhibits the adenylyl cyclase to prevent it from making cAMP. The cAMP produced by the adenylyl cyclase activates cAMP-dependent protein kinase (A-kinase), which is a serine/threonine kinase that in turn activates or inhibits other enzymes to effect a physiological response. For example, in connection with glycogen metabolism, A-kinase may inhibit glycogen synthase to shut down glycogen synthesis, and simultaneously activate phosphorylase kinase that in turn activates glycogen phosphorylase to break down glycogen. A variety of signal substances use cAMP as a second messenger, including calcitonin, chorionic gonadotropin, corticotropin, epinephrine, follicle-stimulating hormone, glucagon, luteinizing hormone, lipotropin, melanocyte-stimulating hormone, norepinephrine, parathyroid hormone (PTH), thyroid-stimulating hormone, and vasopressin. The level of cAMP may be reduced by phosphodiesterases (PDEs), and the activity of kinases may be reversed by phosphatases, as described below.

**[0013]** In the  $\text{Ca}^{2+}$  pathway, the target protein may be a phospholipase with specificity for a phosphoinositide (i.e., inositol phospholipid), and the G-protein may be  $\text{G}_q$ , which activates the phospholipase to cleave the phosphoinositide to produce an intermediate that releases  $\text{Ca}^{2+}$  from the endoplasmic reticulum. For example, the phospholipase phosphoinositide-specific phospholipase C (phospholipase C- $\beta$ ) cleaves the phosphoinositide phosphatidylinositol 4,5-bisphosphate ( $\text{PIP}_2$ ) to produce the second messengers inositol triphosphate ( $\text{IP}_3$ ) and diacylglycerol. The inositol triphosphate is water soluble and diffuses to the endoplasmic reticulum (ER), where it releases  $\text{Ca}^{2+}$  from the ER by binding to  $\text{IP}_3$ -gated  $\text{Ca}^{2+}$ -release channels in the ER membrane. The diacylglycerol is membrane bound and may be cleaved to form the second messenger arachidonic acid or may activate the  $\text{Ca}^{2+}$ -dependent serine/threonine kinase protein kinase C that in turn activates or inhibits other enzymes to effect a response. A variety of signal substances use  $\text{Ca}^{2+}$  as a second messenger, including acetylcholine, thrombin, and vasopressin.

**[0014]** Figure 3 is a schematic view of a representative enzyme-linked cell-surface receptor mechanism 170 that includes a receptor protein 172 positioned across the plasma membrane 174 of a target cell. The receptor protein includes a signal-substance binding site 176 on the extracellular side 178 of the membrane and a catalytic portion 180 on the intracellular side 182 of the membrane. (In some cases, the catalytic portion of the receptor may be replaced or augmented by a separate enzyme directly associated with the receptor protein.) In use, a specific signal substance 184 binds to the signal-substance binding site, initiating a series of events (such as dimerization and concomitant autophosphorylation of the receptor proteins) that activates (\*) the catalytic portion of the receptor. The receptor protein may belong to one of at least five classes of single-pass transmembrane proteins: (A) receptor guanylyl cyclases, which catalyze the production of guanosine 3',5'-cyclic monophosphate (cGMP) in the cytosol; (B) receptor tyrosine kinases, which phosphorylate specific tyrosine residues on some intracellular proteins, (C) tyrosine-kinase-associated receptors, which associate with proteins that phosphorylate specific tyrosine residues on some intracellular proteins; (D) receptor tyrosine phosphatases, which dephosphorylate specific tyrosine residues on some intracellular proteins, and (E) receptor serine/threonine kinases, which phosphorylate specific serine or threonine residues on some intracellular proteins. Some of these receptors are described below in more detail.

**[0015]** The signal substance also may bind to intracellular receptors, such as guanylyl cyclase. This enzyme produces cGMP from GTP, which then acts as a second messenger much like cAMP. As described above, cGMP also may be produced by enzyme-linked cell-surface receptors. cGMP is present in most tissues at levels 1/10 to 1/100 those of cAMP. A variety of compounds increase cGMP levels in cells, including (1) the hormones acetylcholine, insulin, and

oxytocin, (2) the guanylate cyclase stimulators (and vasodilators) nitroprusside, nitroglycerin, sodium nitrate, and nitric oxide, (3) chemicals such as serotonin and histamine, and (4) peptides such as atrial natriuretic peptide (ANP) that relax smooth muscle.

[0016] The level of cyclic nucleotides such as cAMP and cGMP may be controlled by specialized enzymes known as phosphodiesterases (PDEs). These enzymes catalyze the hydrolysis of the 3'-ester bond of cAMP and/or cGMP to form the corresponding uncyclized nucleotide monophosphates AMP and GMP, respectively. More than 30 human PDEs are known, and there is great interest in the pharmaceutical industry in finding inhibitors for PDEs for a broad range of potential therapeutic applications. A selective inhibitor of PDE-5 has been commercialized as the drug Viagra™ (i.e., Sildenafil) for the treatment of male erectile dysfunction. Moreover, several PDE-4 inhibitors are in clinical trials as anti-inflammatory drugs for the treatment of diseases such as asthma

## 2. Intracellular Signaling Pathways

[0017] Target cells may have intracellular signaling pathways capable of specifically binding signal substances, including cell-surface receptors and intracellular receptors, as described above. These pathways may include (1) a phosphorylation pathway involving ATP/ADP, and (2) a GTP-binding pathway involving GTP/GDP.

[0018] Figure 4A is a schematic view of a representative portion of a phosphorylation pathway. Phosphorylation is the predominant mechanism used to regulate protein activity in eucaryotic cells. In phosphorylation, a phosphate group (P) is reversibly attached to the side chain of an amino acid in a protein. The attached phosphate group may cause structural changes in the protein, for example, due to electrostatic interactions between the negative charges on the phosphate group and positive charges on the side chains of nearby amino acids. These structural changes may affect the activity of the phosphorylated protein, enhancing or inhibiting its function.

[0019] Specialized enzymes control phosphorylation in cells. In particular, protein kinase enzymes transfer phosphate groups to proteins, and protein phosphatase enzymes remove phosphate groups from proteins. Protein kinases and protein phosphatases are found in great variety in eucaryotic cells: a single cell may contain more than 100 different kinases, and one percent of genes may code for kinases.

[0020] There are two major categories of protein kinases: (1) serine/threonine (S/T) kinases, and (2) tyrosine kinases. The S/T kinases function by selectively phosphorylating serine and threonine side chains on substrate proteins or peptides. These kinases include cyclic AMP-dependent kinase (A-kinase), cyclic GMP-dependent kinase (G-kinase), protein kinase C (C-kinase), Ca<sup>2+</sup>-calmodulin-dependent kinase (CaM-kinase), phosphorylase kinase, MAP kinase, and TGF-β receptor, among others. The S/T kinases are predominantly cytosolic. The tyrosine kinases function by selectively phosphorylating tyrosine side chains on substrate proteins or peptides. These kinases include the receptor kinases for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), insulin, insulinlike growth factor-1 (IGF-1), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and macrophage colony stimulating factor (M-CSF). These kinases also include the nonreceptor kinases associated with the tyrosine-kinase-associated receptors, such as the Src family (Src, Yes, Fgr, Fyn, Lck, Lyn, Hck, and Blk) and Janus family (JAK1, JAK2, and Tyk2) kinases. The tyrosine kinases are predominantly membrane bound. A few kinases function by selectively phosphorylating threonine and tyrosine side chains on substrate proteins or peptides. These kinases include the mitogen-activated protein (MAP) kinase-kinase.

[0021] Figure 4B is a schematic of a representative portion of a GTP-binding pathway. The GTP-binding pathway generally resembles the phosphorylation pathway in that each pathway involves transfer of a phosphate group to a protein. However, in the GTP-binding pathway, the protein gains a phosphate group by exchanging a bound GDP for a bound GTP, whereas in the phosphorylation pathway, the protein gains a phosphate group by covalent addition of the phosphate group to a serine, threonine, or tyrosine by a kinase enzyme. The binding of a GTP to a GTP-binding protein may cause structural changes in the protein that in turn affect the activity of the protein. Examples of GTP-binding proteins include the trimeric G-proteins described above and the Ras superfamily of monomeric GTPases. The Ras proteins are activated by release of bound GDP and binding of GTP stimulated by guanine-nucleotide releasing proteins (GNRPs). The Ras proteins are inactivated by hydrolysis of the bound GTP by GTPase-activating proteins (GAPs).

[0022] Figure 5 is a schematic view of a representative portion of a second messenger pathway that may follow the receptor activation shown in Figure 4. Specifically, Figure 5 shows the production of cyclic nucleotides by activated receptor cyclases such as adenylyl cyclase and guanylyl cyclase and the degradation of cyclic nucleotides to form the corresponding uncyclized nucleotide monophosphates by phosphodiesterases and/or other mechanisms.

[0023] A physiological response may require stimulation by only a single type of signal substance, or may require stimulation by two or more types of signal substances. The latter mechanism permits finer tuning of the physiological response through signal integration. For example, a protein may be activated only by phosphorylation by two different kinases, themselves activated by binding of two different signal substances to two different receptors. Alternatively, a protein may be activated only by concurrent phosphorylation and GTP binding, or by binding of two subunits whose binding is contingent on phosphorylation by separately activated kinases.

### 3. Effects of Errors

[0024] Errors in the signal transduction and regulation pathways described above can cause cancer and other diseases. Indeed, a primary cause of cancer is a mutation that makes a stimulatory gene product hyperactive, converting a proto-oncogene into an oncogene. The primary classes of known proto-oncogenes include the following cell-signaling proteins: (1) growth-factor receptors acting via tyrosine kinases, (2) GTP binding proteins, (3) membrane/cytoskeleton-associated tyrosine kinases, (4) cytoplasmic tyrosine kinases, (5) steroid-type growth-factor receptors, and (6) S/T kinases. Consequently, cell-signaling proteins have become important subjects of research and drug development.

### 4. Selected Shortcomings of Current Assays

[0025] Assays that determine the presence and/or activity of cell-signaling components are important tools in life sciences research, including high-throughput screening. Unfortunately, current assays have a number of shortcomings.

[0026] The presence and activity of kinases, for example, can be determined using assays capable of detecting phosphorylated amino acids. In a standard kinase assay, radioactive ATP and an appropriate protein substrate are added to a sample. If the sample includes kinases, radioactive phosphate groups will be transferred from the radioactive ATP to the protein substrate. The presence and activity of kinases can be determined by assaying the amount of radioactive protein substrate, for example, using heterogeneous methods such as a filter plate that involve separating the protein substrate and radioactive ATP, or homogeneous methods such as a scintillation proximity assay for detecting radioactive decay. Unfortunately, both approaches involve radioactivity, presenting a short-term safety hazard for the assay operator and a longterm storage and disposal problem.

[0027] In an alternative kinase assay, ATP, a luminescent protein, and an antibody against a phosphorylated form of the luminescent protein are added to a sample. If the sample includes kinases, the kinases will transfer phosphate groups from the ATP to the protein, the antibody will bind to the phosphorylated protein, and the luminescence polarization of the protein will increase (because its rotational mobility will decrease). Unfortunately, the binding of antibodies is very target specific, so that in general a different antibody will be needed for each substrate (depending on the sequence of the substrate, including whether a tyrosine, serine, or threonine is to be phosphorylated). This shortcoming is especially significant for serines and threonines. Thus, a different antibody may be needed for each of the many kinases, depending on the polypeptide sequences of the corresponding substrates. Yet, suitable antibodies may be unavailable for many substrates and kinases, especially for poorly studied or previously unstudied kinases, or take several months or more to prepare.

[0028] Significantly, assays for other cell-signaling components (such as phosphatases, phosphodiesterases, and/or cyclases) may have similar shortcomings, such as the use of radioactive reagents, if the assays exist at all. Moreover, these assays may have slow time courses and unstable endpoints that require precise timing of assay readouts. Thus, there is a need for improved assays for detecting enzyme activity, and in particular the presence and activity of cell-signaling components.

### Summary of the Invention

[0029] The invention provides a method of assaying cyclization or decyclization of a nucleotide in a sample, comprising: contacting a nucleotide with a binding partner that binds specifically to cyclized nucleotide or to noncyclized nucleotide, but not both; and detecting a response indicative of binding, or of the extent of binding, between the cyclized or noncyclized nucleotide and the binding partner, characterised in that the binding partner includes a metal ion that is required for binding between the binding partner and the cyclized or noncyclized nucleotide.

[0030] Further embodiments of the invention are set forth in the attached paragraphs.

### Brief Description of the Drawings

[0031]

Figure 1 is a schematic view of a cell-signaling pathway.

Figure 2 is a schematic view of a G-protein-linked cell-surface receptor mechanism that includes a receptor protein, a G-protein, and a target protein, all associated with the plasma membrane of a target cell.

Figure 3 is a schematic view of an enzyme-linked cell-surface receptor mechanism that includes a receptor protein positioned across the plasma membrane of a target cell.

Figure 4 is a schematic view of two common intracellular signaling pathways: (A) a phosphorylation pathway involving ATP/ADP, and (B) a GTP-binding pathway involving GTP/GDP.

Figure 5 is a schematic view of a representative portion of a second messenger pathway that may follow the receptor

activation shown in Figure 4.

Figure 6 is a schematic view of species and/or reactions that may be analyzed using assays provided by the invention.

Figure 7 is a flowchart showing steps that may be used alone, together, or in combination with other steps to construct assays according to various aspects of the invention.

Figure 8 is a bar graph showing results from an end-point study for cGMP PDE activity using MANT-cGMP and MM-Ga under the following conditions: (1) reaction with enzyme, with MM-Ga, (2) reaction with enzyme, without MM-Ga (3) reaction without enzyme, with MM-Ga (4) reaction without enzyme, without MM-Ga.

Figure 9 is a graph showing results from a time-course study conducted using the system of Figure 8.

Figure 10 is a graph showing results from a time-course study for cGMP PDE activity using fluorescein-cGMP and MM-GA.

Figure 11 is a graph showing an IC<sub>50</sub> measurement of Zaprinast using the system of Figure 10.

Figure 12 is a graph showing the detection of PDE 4 activity using a fluorescein-labeled cAMP substrate.

Figure 13 is a graph showing the detection of PDE 5 activity using a fluorescein-labeled cGMP substrate using the conditions of Figure 12.

Figure 14 is a graph showing the detection of PDE 1 activity using fluorescein-labeled cAMP and fluorescein-labeled cGMP substrates under the conditions of Figure 12.

## Definitions

**[0032]** The various technical terms used herein generally have the meanings that are commonly recognized by those skilled in the art. However, the following terms may have additional and/or alternative meanings, as described below:

**Cyclization / decyclization** - the formation or degradation of a ring connecting a phosphate group and a nucleoside in a nucleotide. A common cyclization forms cAMP and cGMP from ATP and GTP, respectively, by removing two phosphate groups from the nucleotide triphosphates and joining the "free" end of the remaining phosphate group to the sugar in the remaining nucleotide monophosphate. A common decyclization reaction degrades the ring to form AMP and GMP from cAMP and cGMP, respectively.

**Immunoglobulin** - a group of typically large glycoproteins secreted by plasma cells in vertebrates that function as antibodies in the immune response by binding to specific antigens.

**Luminescent** - capable of, suitable for, or exhibiting luminescence, which is the emission of light by sources other than a hot, incandescent body. Luminescence is caused by electronic transitions within a luminescent substance (or lumino-phore) from more energetic to less energetic states. Among several types are chemiluminescence, electrochemiluminescence, electroluminescence, photoluminescence, and triboluminescence, which are produced by chemical reactions, electrochemical reactions, electric discharges, absorption of light, and the rubbing or crushing of crystals, respectively. Molecules may be intrinsically and/or extrinsically luminescent, meaning that they are luminescent on their own or luminescent due to covalent and/or noncovalent association with another molecule that is luminescent.

**Nucleotide** - a compound comprising a nucleoside and a phosphate group, some of which function as cell regulators and some of which function as the basic constituent of DNA and RNA. A nucleoside in turn is a compound comprising a sugar, such as ribose or deoxyribose, and a purine or pyrimidine base, such as adenine, cytosine, guanine, thymine, or uracil. Nucleotides are named according to the identities of their constituent bases and sugars, the number of their constituent phosphates, and the presence or absence of cyclization. Suitable nucleotides are listed in the following table:

<i>Nucleotide</i>	<i>Abbreviation</i>
Adenosine cyclic monophosphate	cAMP
Cytidine cyclic monophosphate	cCMP
Guanosine cyclic monophosphate	cGMP
Thymidine cyclic monophosphate	cTMP
Uridine cyclic monophosphate	cUMP
Adenosine monophosphate	AMP
Cytidine monophosphate	CMP
Guanosine monophosphate	GMP
Thymidine monophosphate	TMP
Uridine monophosphate	UMP

**Phosphorylation / dephosphorylation** - the introduction or removal of a phosphate group to or from an organic molecule such as a polypeptide. Phosphorylation is a versatile posttranslational modification that is a recurrent theme for regulation

of enzyme activity and signal transduction pathways.

**Polypeptide** - a polymer comprising two or more amino acid residues linked together by covalent bonds, typically from amino end to carboxyl end by peptide bonds, and modifications and complexes thereof. Polypeptides generally include peptides and/or proteins, among others. Here, peptide generally refers to smaller polypeptides (e.g., less than about 100, 50, 20, or 10 amino acids, among others), and protein generally refers to larger polypeptides, and complexes thereof, possibly modified by other organic or inorganic conjugated chemical groups, such as phosphates, sugars, and so on. Polypeptides may include straight chains and/or branched chains, among others. Suitable amino acids are listed in the following table:

<i>Amino acid</i>	<i>Three-letter abbreviation</i>	<i>One-letter abbreviation</i>
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Asparagine or aspartic acid	Asx	B
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glutamine or glutamic acid	Glx	Z
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

**Specific binding** - binding to a specific binding partner to the exclusion of binding to most other moieties. Specific binding can be characterized by a binding coefficient. Generally, specific binding coefficients range from  $10^{-4}$  M to  $10^{-12}$  M and lower, and preferred specific binding coefficients range from  $10^{-8}$  or  $10^{-9}$  M to  $10^{-12}$  M and lower.

### **Detailed Description**

**[0033]** The invention provides assays for detecting molecular modifications and the presence and/or activity of enzymes and other agents involved in facilitating or otherwise regulating such modifications. The modifications are the cyclization and decyclization of molecules such as nucleotides. The enzymes may include among others enzymes involved in performing and/or regulating phosphorylation, dephosphorylation, cyclization, and decyclization modifications, such as kinases, phosphatases, cyclases, and phosphodiesterases (PDEs), respectively. The assays may include among others luminescence assays, such as luminescence polarization, luminescence resonance energy transfer, and/or luminescence intensity. The assays provided by the invention may be useful in a variety of applications, including without limitation life science research, drug research, accelerated drug discovery, assay development, and high-throughput screening, among others.

### **1. Overview**

**[0034]** Figure 6 shows species and/or reactions that may be analyzed using assays provided by the invention. The

species include reactant and product A and A\*, respectively, enzymes  $E_{AA^*}$  and  $E_{A^*A}$ , and/or enzyme modulators  $M_{E_{AA^*}}$  and  $M_{E_{A^*A}}$ , among others. The assays may be used to analyze the presence and/or quantity of A and/or A\*. Alternatively, or in addition, the assays may be used to analyze the presence and/or activity of  $E_{AA^*}$ ,  $E_{A^*A}$ ,  $M_{E_{AA^*}}$ , and/or  $M_{E_{A^*A}}$ . Quantity refers generally to amount, which may be defined intrinsically and/or extrinsically, for example, using concentration and/or number or mass, respectively. Activity refers generally to rate, which may be defined as the rate of substrate consumption and/or product formation per time. Here, quantity and/or amount may be used so as to encompass the simple presence of components, and activity and/or rate may be used so as to encompass the simple presence of activity.

**[0035]** A and A\* generally comprise any two species related by a modification (denoted by the presence or absence of \*). A and A\* are molecules and assemblies of molecules such as nucleotides. The modification may include phosphate modifications such as cyclization, and/or decyclization. A and A\* may be related as substrate and product in a reaction, such as an enzyme-catalyzed reaction. Thus, depending on the direction of the reaction, A and A\* in a phosphate modification may be a cyclized nucleotide, or a noncyclized nucleotide. In some embodiments, A and/or A\* may include components intended to facilitate detection of binding between A or A\* and BP, such as a luminophore, a quencher, an energy transfer partner, and the like.

**[0036]** BP generally comprises any binding partner capable of binding specifically to A or A\* (i.e., the modified species or the unmodified species) but not to both. BP may include any binding partner having the specified binding properties that does not include a polypeptide and/or an immunoglobulin, and/or a functional portion or fragment thereof. BP includes one or more metal ions, including dicationic, tricationic, and polycationic metal ions, among others. Suitable dicationic metal ions include iridium ( $Ir^{2+}$ ), osmium ( $Os^{2+}$ ), platinum ( $Pt^{2+}$ ), rhenium ( $Re^{2+}$ ), and ruthenium ( $Ru^{2+}$ ), among others. Suitable tricationic metal ions include including aluminum ( $Al^{3+}$ ), chromium ( $Cr^{3+}$ ), iron ( $Fe^{3+}$ ), gallium ( $Ga^{3+}$ ), manganese ( $Mn^{3+}$ ), scandium ( $Sc^{3+}$ ), titanium ( $Ti^{3+}$ ), vanadium ( $V^{3+}$ ), and/or yttrium ( $Y^{3+}$ ), among others. Preferred metal ions include aluminum, iron, and gallium. The metal ions may interact with or otherwise be involved in or required for binding with the modification on A or A\*, such as the phosphate group on a noncyclized nucleotide. Alternatively, or in addition, BP may include one or more charged portions to facilitate or otherwise participate in the binding reaction with A or A\*, particularly charged portions that are immobilized relative to BP. Alternatively, or in addition, BP may bind to a substrate such as A or A\* only if it is phosphorylated, where the binding between the substrate and the binding partner is substantially nonspecific with respect to the structure of the substrate aside from any phosphate groups. Thus, the binding may occur substantially without regard to the target amino acid or surrounding amino acid sequence in a phosphorylation/dephosphorylation assay, or the base or nucleoside in a cyclization/decyclization assay. Alternatively, or in addition, BP may include a macromolecule and/or a particle. Here, particles include nanoparticles and microparticles, among others, where nanoparticles are particles with at least one dimension less than about 100 nm, and microparticles are particles with dimensions between about 100 nm and about 10  $\mu m$ . Alternatively, or in addition, BP may be linked to an associated solid phase, such as a bead, membrane, or sample holder, among others. The link may be formed using any suitable mechanism, including hydrogen bonding, ionic bonding, electrostatic binding, hydrophobic interactions, Van der Waals interactions, and/or covalent attachment, among others. In some embodiments, BP may include components intended to facilitate detection of binding between BP and A or A\*, such as a luminophore, a quencher, an energy transfer partner, and the like.

**[0037]**  $E_{AA^*}$  and  $E_{A^*A}$  generally comprise any enzymes or other catalysts capable of facilitating reactions converting A to A\* and A\* to A, respectively.  $E_{AA^*}$  and  $E_{A^*A}$  may include enzymes such as cyclases and phosphodiesterases, which catalyze the cyclization and decyclization of nucleotides, respectively.

**[0038]**  $M_{E_{AA^*}}$  and  $M_{E_{A^*A}}$  generally comprise any modulators or other agents capable of modulating or otherwise affecting the activity of  $E_{AA^*}$  and  $E_{A^*A}$ , respectively. The modulator may be a change in environmental condition, such as a change in sample temperature, but more typically is an enzyme or other reagent added to the sample. The modulator may be a chemical reagent, such as an acid, base, metal ion, organic solvent, and/or other substance intended to effect a chemical change in the sample. Alternatively, or in addition, the modulator may have or be suspected to have a biological activity or type of interaction with a given biomolecule, such as an enzyme, drug, oligonucleotide, nucleic acid polymer, peptide, protein, and/or other biologically active molecule. The modulator may include an agonist or inhibitor capable of promoting or inhibiting, respectively, the activity of the modulated enzyme. For example, in a cyclic nucleotide assay, preferred agonists include forskolin and isoproterenol, and preferred inhibitors include propranolol and Zaprinast.

## 2. Assays

**[0039]** Figure 7 shows several steps that may be used alone, together, or in combination with other steps to construct assays. These steps may include (1) contacting at least one member of a pair of molecules or other entities related by a modification as described above with a binding partner capable of binding one of the pair of molecules but not the other as described above, (2) detecting a response indicative of the extent of binding between the at least one member of the pair and the binding partner, and (3) correlating the response with the extent of modification, or with the presence and/or activity of an enzyme that affects the modification. The assays further may include contacting the at least one



member with the enzyme before and/or after the steps of contacting, detecting, and correlating. The assays further may include contacting the at least one member and the enzyme with a candidate compound such as a putative modulator before and/or after the step of contacting the at least one member with the enzyme, and determining the ability of the candidate compound to promote or inhibit the modification by its effects on the extent of binding. Alternatively, or in addition, the assays further may include washing the sample including the at least one member and the binding partner to remove any member of the pair not bound to the binding partner prior to the step of detecting the extent of binding. The assays may include repeating the steps of contacting, detecting, and/or correlating for the same sample and/or a plurality of different samples. For example, the assays may involve providing a sample holder having a plurality of sample sites supporting a corresponding plurality of samples, and sequentially and/or simultaneously repeating the steps of contacting, detecting, and/or correlating for the plurality of samples. The remainder of this section describes in more detail the steps of (1) contacting, (2) detecting, and (3) correlating.

## 1. Contacting

**[0040]** The step of contacting assay components such as enzymes, enzyme modulators, substrates, products, and/or binding partners with one another and/or with other species generally comprises any method for bringing any specified combination of these components into functional and/or reactive contact. A preferred method is by mixing and/or forming the materials in solution, although other methods, such as attaching one or more components such as the binding partner to a bead or surface, also may be used, as long as the components retain at least some function, specificity, and/or binding affinity following such attachment.

**[0041]** One of more of the assay components may comprise a sample, which typically takes the form of a solution containing one or more biomolecules that are biological and/or synthetic in origin. The sample may be a biological sample that is prepared from a blood sample, a urine sample, a swipe, or a smear, among others. Alternatively, the sample may be an environmental sample that is prepared from an air sample, a water sample, or a soil sample, among others. The sample typically is aqueous but may contain biologically compatible organic solvents, buffering agents, inorganic salts, and/or other components known in the art for assay solutions.

**[0042]** The assay components and/or sample may be supported for contact and/or analysis by any substrate or material capable of providing such support. Suitable substrates may include microplates, PCR plates, biochips, and hybridization chambers, among others, where features such as microplate wells and microarray (i.e., biochip) sites may comprise assay sites. Suitable microplates may include 96, 384, 1536, or other numbers of wells. These microplates also may include wells having small ( $\leq 50 \mu\text{L}$ ) volumes, elevated bottoms, and/or frusto-conical shapes capable of matching a sensed volume. Suitable PCR plates may include the same (or a similar) footprint, well spacing, and well shape as the preferred microplates, while possessing stiffness adequate for automated handling and thermal stability adequate for PCR. Suitable microarrays include nucleic acid and polypeptide microarrays, which are described in Bob Sinclair, Everything's Great When It Sits on a Chip: A Bright Future for DNA Arrays, 13 THE SCIENTIST, May 24, 1999, at 18. Suitable hybridization chambers are described in PCT Patent Application Serial No. PCT/US99/03678, filed February 19, 1999, published as WO 99/042817.

## 2. Detecting

**[0043]** The step of detecting a response indicative of the extent of binding generally comprises any method for effectuating such detection, including detecting and/or quantifying a change in, or an occurrence of, a suitable parameter and/or signal. The method may include luminescence and/or nonluminescence methods, and heterogeneous and/or homogeneous methods, among others.

**[0044]** Luminescence and nonluminescence methods may be distinguished by whether they involve detection of light emitted by a component of the sample. Luminescence assays involve detecting light emitted by a luminescent compound (or luminophore) and using properties of that light to understand properties of the compound and its environment. A typical luminescence assay may involve (1) exposing a sample to a condition capable of inducing luminescence from the sample, and (2) measuring a detectable luminescence response indicative of the extent of binding between the member of interest and a corresponding binding partner. Most luminescence assays are based on photoluminescence, which is luminescence emitted in response to absorption of suitable excitation light. However, luminescence assays also may be based on chemiluminescence, which is luminescence emitted in response to chemical excitation, and electrochemiluminescence, which is luminescence emitted in response to electrochemical energy. Suitable luminescence assays include, among others, (1) luminescence intensity, which involves detection of the intensity of luminescence, (2) luminescence polarization, which involves detection of the polarization of light emitted in response to excitation by polarized light, and (3) luminescence energy transfer, which involves detection of energy transfer between a luminescent donor and a suitable acceptor. These and other luminescence assays are described below in Example 14 and materials cited therein. Nonluminescence assays involve using a detectable response other than light emitted by the sample, such

as absorption, scattering, and/or radioactivity, among others. These and other nonluminescence assays are described in Joseph R. Lakowicz, *Principles of Fluorescence Spectroscopy* (2nd ed. 1999).

**[0045]** The detectable luminescence response generally comprises a change in, or an occurrence of, a luminescence signal that is detectable by direct visual observation and/or by suitable instrumentation. Typically, the detectable response is a change in a property of the luminescence, such as a change in the intensity, polarization, energy transfer, lifetime, and/or excitation or emission wavelength distribution of the luminescence. The detectable response may be simply detected, or it may be quantified. A response that is simply detected generally comprises a response whose existence merely is confirmed, whereas a response that is quantified generally comprises a response having a quantifiable (e.g., numerically reportable) value such as an intensity, polarization, and/or other property. In luminescence assays, the detectable response may be generated directly using a luminophore associated with an assay component actually involved in binding such as A\* or BP, or indirectly using a luminophore associated with another (e.g., reporter or indicator) component. Suitable methods and luminophores for luminescently labeling assay components are described in Richard P. Haugland, *Handbook of Fluorescent Probes and Research Chemicals* (6th ed. 1996).

**[0046]** Heterogeneous and homogeneous methods may be distinguished by whether they involve sample separation before detection. Heterogeneous methods generally require bulk separation of bound and unbound species. This separation may be accomplished, for example, by washing away any unbound species following capture of the bound species on a solid phase, such as a bead or microplate surface labeled with a tricationic metal ion or other suitable binding partner. The extent of binding then can be determined directly by measuring the amount of captured bound species and/or indirectly by measuring the amount of uncaptured unbound species (if the total amount is known). Homogeneous methods, in contrast, generally do not require bulk separation but instead require a detectable response such as a luminescence response that is affected in some way by binding or unbinding of bound and unbound species without separating the bound and unbound species. Homogeneous assays typically are simpler to perform but more complicated to develop than heterogeneous assays.

### 3. Correlating

**[0047]** The step of correlating generally comprises any method for correlating the extent of binding with the extent of modification of the assay component being analyzed, and/or with the presence and/or activity of an enzyme that affects the modification. The nature of this step depends in part on whether the detectable response is simply detected or whether it is quantified. If the response is simply detected, it typically will be used to evaluate the presence of a component such as a substrate, product, and/or enzyme, or the presence of an activity such as an enzyme or modulator activity. In contrast, if the response is quantified, it typically will be used to evaluate the presence and/or quantity of a component such as a substrate, product, and/or enzyme, or the presence and/or activity of a component such as an enzyme or modulator.

**[0048]** The correlation generally may be performed by comparing the presence and/or magnitude of the response to another response (e.g., derived from a similar measurement of the same sample at a different time and/or another sample at any time) and/or a calibration standard (e.g., derived from a calibration curve, a calculation of an expected response, and/or a luminescent reference material). Thus, for example, in a polarization assay for cyclic nucleotide concentration, the cyclic nucleotide concentration in an unknown sample may be determined by matching the polarization measured for the unknown with the cyclic nucleotide concentration corresponding to that polarization in a calibration curve generated under similar conditions by measuring polarization as a function of cyclic nucleotide concentration. More generally, the following table shows representative qualitative changes in the indicated detectable luminescence response upon binding between A\* and BP following a forward reaction  $A \rightarrow A^*$ .

Label on A*	Label on BP	Intensity (Luminophore)	Intensity (Acceptor)	FP (Luminophore)	ET (Lum. → Acc.)
Luminophore	—			Increases	
—	Luminophore			Increases	
Luminophore	Quencher	Decreases			
Quencher	Luminophore	Decreases			
Luminophore	Acceptor	Decreases	Increases	Decreases	Increases
Acceptor	Luminophore	Decreases	Increases		Increases

This reaction is representative of a phosphorylation reaction performed by a kinase or a decyclization reaction performed

by a PDE, assuming that the binding partner binds to the (noncyclized) phosphorylated species. Similarly, the following table shows representative qualitative changes in the indicated detectable luminescence response upon binding of A\* and BP following the reverse reaction  $A^* \rightarrow A$ .

Label on A*	Label on BP	Intensity (Luminophore)	Intensity (Acceptor)	FP (Luminophore)	ET (Lum. $\rightarrow$ Acc.)
Luminophore	—			Decreases	
—	Luminophore			Decreases	
Luminophore	Quencher	Increases			
Quencher	Luminophore	Increases			
Luminophore	Acceptor	Increases	Decreases	Increases	Decreases
Acceptor	Luminophore	Increases	Decreases		Decreases

This reaction is representative of a dephosphorylation reaction performed by a phosphatase or a cyclization reaction performed by a cyclase, assuming again that the binding partner binds to the (noncyclized) phosphorylated species.

### 3. Examples

**[0049]** The following examples describe without limitation further aspects of the invention. These aspects include (1) the ability of binding partners such as tricationic metal ions to bind specifically to phosphorylated species such as nucleotides, and (2) the use of such binding in assays for enzymes and other agents involved in cyclization and decyclization (e.g., cyclases and PDEs, respectively), among others. These aspects are applicable to a wide variety of enzymes and enzyme substrates and products.

#### Example 1

**[0050]** This example describes a macromolecular trapping system for use in luminescence polarization and/or energy transfer assays, among others, in accordance with aspects of the invention. In this system,  $Ru^{2+}$  is entrapped in small (~20-30 kDa) synthetic polymer macromolecules (MM), which are obtained from PreSens Precision Sensing (Neuburg/Donau, Germany). These macromolecules are relatively hydrophilic, with carboxyl groups on their surfaces for activation. The MM with the entrapped  $Ru^{2+}$  is used as a support to immobilize tricationic metal cations, including  $Fe^{3+}$  and  $Ga^{3+}$ . Specifically, the chelator imidodiacetic (IDA) acid is linked to the MM using the secondary amine group of IDA and a carboxyl group on the MM. Afterwards, the MM-IDA is incubated with either  $FeCl_3$  or  $GaCl_3$ . The  $FeCl_3$  quenches the luminescence of  $Ru^{2+}$ , whereas the  $GaCl_3$  does not. The macromolecule loaded with  $Fe^{3+}$  or  $Ga^{3+}$  is denoted MM-Fe or MM-Ga, respectively.

**[0051]** The macromolecular trapping system may be used in a variety of kinase, phosphatase, phosphodiesterase, and/or cyclase assays, as described below in Examples 3-5 and 7-9. In an exemplary assay, a kinase enzyme phosphorylates a luminescently labeled kinase substrate, which binds to the metal cations immobilized on the MM. Binding is detected using polarization and/or energy transfer methods, among others, for example, using apparatus and methods as described herein. Binding is detectable using polarization because binding leads to a decrease in substrate mobility and a concomitant increase in the polarization of light emitted by luminophores bound to the substrate. Similarly, binding is detectable using energy transfer because binding leads to a decrease in separation between the luminophores bound to the substrate and the  $Ru^{2+}$  immobilized in the MM, and a concomitant increase in energy transfer from the  $Ru^{2+}$  (donor) to the luminophore (acceptor).

**[0052]** This approach may be extended by various modifications and/or substitutions. For example, in polarization assays, the  $Ru^{2+}$  may be omitted, if desired. In energy transfer assays, the  $Ru^{2+}$  may be replaced by any energy transfer partner, as long as the energy transfer partner supported by the MM is capable of energy transfer to or from a complementary energy transfer partner supported by the species binding to the MM. Also, the  $Ru^{2+}$  or its analog does not need to be encapsulated in the MM. A luminescent species may be attached directly to a suitable  $Fe^{3+}$  or  $Ga^{3+}$  chelate. In a heterogeneous assay, phosphorylated proteins bound via  $Ga^{3+}$  or  $Fe^{3+}$  to microplates, particles, or inner surfaces of microfluidic devices may be detected after a wash by measuring luminescence intensity. Such detection can take place either directly on the surfaces or in the solution phase by adding an elution solution such as a phosphate buffer. With other detection methods, such as the laser-scanning method used in fluorometric microvolume assay technology (FMAT™) technology (PE Biosystems, Foster City, California), the bound phosphoproteins can be detected directly on


the beads, without the need for washing or separation. Other labels such as enzymes also may be used in the heterogeneous format.

**[0053]** Potential difficulties with this system include (1) interference from compounds (e.g., ATP, free phosphate, EDTA, and possibly primary/secondary amines) that may compete with or otherwise affect the interaction between the metal and the phosphorylated protein, and (2) difficulty in maintaining a pH that preserves the affinity and selectivity of the binding between the metal and phosphorylated protein.

### Example 2

**[0054]** This example describes assays for the presence, activity, substrates, and/or products of phosphodiesterases in accordance with aspects of the invention. Similar assays may be used to analyze cyclases in which the substrate of the phosphodiesterase reaction becomes the product of the cyclase reaction.

**[0055]** Phosphodiesterases (PDEs) catalyze the decyclization of cyclic nucleotides to the corresponding noncyclized nucleotide monophosphate, as shown below:



Thus, the presence and/or activity of a PDE may be detected by a decrease in the concentration of a cyclic nucleotide (cNMP) substrate and/or by an increase in the concentration of a corresponding uncyclized nucleotide monophosphate (NMP) product. (The presence and/or activity of a cyclase may be detected similarly by a decrease in the concentration of a nucleotide triphosphate substrate and/or by an increase in the concentration of a corresponding cyclic nucleotide.) The invention provides among others PDE assays that involve contacting a sample containing a candidate PDE (and optionally a modulator thereof) with a luminescently labeled cyclic nucleotide and a binding partner that binds specifically to the corresponding uncyclized nucleotide monophosphate but not to the cyclic nucleotide. The binding partner may include one or more of the attributes described above, such as a tricationic metal  $M^{3+}$  (e.g.,  $Al^{3+}$ ,  $Ga^{3+}$ , and/or  $Fe^{3+}$ ) capable of binding an uncyclized phosphate group but not a cyclized phosphate group, and optionally an energy transfer partner and/or quencher. PDE activity may be detected by an increase in NMP binding using any technique capable of measuring such an increase, including luminescence polarization, luminescence resonance energy transfer, luminescence intensity, and/or nonluminescence and/or heterogeneous techniques, among others. For example, PDE activity may be detected following NMP binding by (1) an increase in luminescence polarization (assuming that the lifetime and rotational correlation time of the binding partner are selected so that binding of the NMP to the binding partner measurably decreases the rotational correlation time of the NMP), (2) an increase in luminescence resonance energy transfer (assuming that the binding partner is associated with a suitable energy transfer partner), and/or (3) a decrease in luminescence intensity (assuming that the binding partner is associated with a suitable luminescence quencher).

**[0056]** The assays may include (1) contacting a sample containing a candidate PDE (and/or other cell-signaling component) with a luminescently labeled cyclic nucleotide and a binding partner capable of distinguishing between the cyclic nucleotide and the corresponding nucleotide monophosphate, (2) illuminating the sample with light capable of inducing luminescence in the sample, (3) measuring a property of the luminescence transmitted from the sample, and (4) correlating the property with the presence and/or activity of the cyclic nucleotide and/or the corresponding nucleotide monophosphate and hence the presence and/or activity of an associated enzyme.

**[0057]** The invention also provides methods for identifying modulators such as agonists and inhibitors of receptors and/or enzymes involved in the production and/or regulation of cell-signaling molecules, such as the hydrolysis of cyclic nucleotides. The methods may include looking for the effects of a modulator by conducting a method for determining the concentration of a cyclic nucleotide and/or the corresponding nucleotide monophosphate in both the presence and absence of the putative modulator. For example, in a polarization assay in which PDE activity leads to an increase in polarization, a decrease in the measured extent of polarization of the emitted light in the presence of the putative modulator identifies the putative modulator as an inhibitor of the receptor or enzyme, and an increase in the measured extent of polarization in the presence of the putative modulator identifies the putative modulator as an agonist of the receptor or enzyme.

### Example 3

**[0058]** This example describes end-point and time-course assays for PDE 5 in accordance with aspects of the invention,

showing in part the utility of the MM-Ga system in PDE assays. These assays use the following components, among others: (1) cGMP-specific PDE (type V, Calbiochem, La Jolla, California), (2) N-methylanthraniloyl (MANT) cGMP substrate (Molecular Probes, Eugene, Oregon), and (3) MM-Ga, as described in Example 1. MANT is a compact blue-fluorescing luminophore that attaches to the cGMP via the ribose ring of the cGMP. These assays show the utility of the

**[0059]** Figure 8 shows results of an end-point assay. Here, 1  $\mu$ L (50 units) of cGMP specific PDE is added to 50  $\mu$ L of 5  $\mu$ M MANT-cGMP in a HEPES buffer (pH 7.5). The tube is incubated at room temperature for 60 minutes. Then, 10  $\mu$ L of the reaction mixture is added to 40  $\mu$ L of MES/BSA buffer (pH 5.5) containing approximately 0.8  $\mu$ M MM-Ga. The resulting mixture is incubated at room temperature for 30 minutes. Then, the luminescence polarization is measured (for MANT, excitation 360 nm, emission 480 nm) using an ANALYST™ light-detection platform (Molecular Devices Corporation, Sunnyvale, California). Results correspond to the following conditions: (1) reaction with enzyme, with MM-Ga, (2) reaction with enzyme, without MM-Ga (3) reaction without enzyme, with MM-Ga, and (4) reaction without enzyme, without MM-Ga. These experiments show that the cyclic GMP and the MM-Ga bind to one another specifically.

**[0060]** Figure 9 shows results of a time-course assay. Here, a 50- $\mu$ L solution containing 100  $\mu$ M MANT-cGMP and 100 units of PDE in HEPES buffer (pH 7.5) is incubated at room temperature. At each time point, 2  $\mu$ L of reaction mixture is removed from the tube and diluted into 200  $\mu$ L of MES/BSA buffer (pH 5.5). After 2 hours, 45  $\mu$ L of each diluted reaction solution is mixed with 5  $\mu$ L of MM-Ga (approx. 6.4  $\mu$ M) and incubated at room temperature for 30 minutes before the fluorescence polarization is measured.

#### **Example 4**

**[0061]** This example describes alternative PDE assays in accordance with aspects of the invention. These assays are presented in a homogenous, nonradioactive format using a carboxyfluorescein labeled cGMP substrate. The assay also may be used in a heterogeneous format and/or with an alternative luminescent cGMP and/or cAMP. These assays further show the utility of the MM-Ga system for detection of noncyclized GMP and the presence and/or activity of cGMP-specific PDEs, including the use of a different luminophore than the MANT of Example 3.

**[0062]** Figure 10 shows results of a time-course assay conducted using fluorescein-cGMP and the PDE and binding partner of Example 3. Here, 2.0  $\mu$ M fluorescein-cGMP is incubated with 0.5 unit of PDE (V) in a buffer containing 40 mM MOPS (pH 7.5), 0.5 mM EDTA, 15 mM MgCl<sub>2</sub>, and 0.15 mg/mL BSA in a total volume of 50  $\mu$ L. At each time point, 1  $\mu$ L of the reaction mixture is removed and diluted into 200  $\mu$ L of MES buffer (pH 5.5), and the diluted solution is placed on ice. After the reaction, 25  $\mu$ L of the diluted solution is mixed with an equal volume of a MM-Ga solution, and incubated at room temperature for 30 minutes before the luminescence polarization value is measured.

**[0063]** Figure 11 shows results of an inhibition assay using the components of Figure 10. Here, the assay was used to measure the IC<sub>50</sub> of the known PDE (V) inhibitor, Zaprinast, using 0.5  $\mu$ M fluorescein-cGMP and a reaction time of 30 min. These experiments show that the IC<sub>50</sub> is about 0.1  $\mu$ M, in reasonable agreement with the literature value of about 0.3  $\mu$ M determined using a radioactive assay with <sup>3</sup>H-cGMP as the substrate.

#### **Example 5**

**[0064]** This example describes several aspects of the invention, including (1) use of Ga<sup>3+</sup>-coated nanoparticles as the binding component in the assay, (2) applications to the detection of PDE 4 enzyme, with fluorescein-labeled cAMP as substrate, and (3) applications to the detection of PDE 1 enzyme, with both fluorescein-labeled cAMP and fluorescein-labeled cGMP as substrates.

**[0065]** As discussed in Example 1, synthetic polymer macromolecules (MM) can be substituted with other materials that have a high molecular weight and that tricationic cations (i.e., Fe<sup>3+</sup>, Ga<sup>3+</sup>) can be immobilized on. Here, we use selected nanoparticles, including polystyrene nanoparticles having an average diameter of about 40 nm. The nanoparticles are from Bangs Laboratory (Fisher, Indiana), and are modified after acquisition from the vendor to attach Ga<sup>3+</sup> on the surfaces of the particles.


**[0066]** Figure 12 shows the detection of PDE 4 activity using a fluorescein-labeled cAMP (FL-cAMP) substrate. PDE 4 was obtained from Dr. Macro Conti at Stanford University. In this assay, 10  $\mu$ L of a solution containing 40 nM of FL-cAMP is mixed with 10  $\mu$ L of a series of solutions containing various concentrations of PDE 4 in a black 384-well plate. The mixture is incubated at room temperature for 45 min, and then 60  $\mu$ L of a solution containing 0.16 mg/mL of the modified nanoparticles is added. The new mixture is incubated for 30 min, and then the luminescence polarization is measured.

**[0067]** Figure 13 shows similar results using PDE 5 (Calbiochem, La Jolla, CA) as the enzyme and a fluorescein-labeled cGMP (FL-cGMP) as the substrate under the conditions of Figure 12.

**[0068]** Figure 14 shows similar results using PDE 1 (Sigma, St. Louis, MO) as the enzyme and both FL-cAMP and FL-cGMP as substrates under the conditions of Figure 12. PDE 1 is another isozyme in the PDE family of enzymes,

which acts on both FL-cAMP and FL-cGMP. The PDE 1 used here is activated according to the vendor's instructions.

**[0069]** This example shows representative tracers for use in cyclic nucleotide assays, particularly luminescence-polarization-based cyclic nucleotide assays. General structures for such tracers are shown below for (A) cAMP and (B) cGMP:



Here, X and R1 represent linkers, which optionally and independently may be present or absent, and Fl represents a reporter species. X may include among others any alkyl, allyl, or aryl linker with ester or ether bonds to the cyclic nucleotide, including  $\text{-OC(=O)-CH}_2\text{CH}_2\text{C(=O)-}$ . R1 may be any linker joining Fl to the nucleotide, directly, or indirectly through X, including a rigid linker having (two) reactive groups for coupling, one to Fl and one to the nucleotide. For example, R1 may be a diamino-alkyl, -cycloalkyl, -aryl, or -allyl group, or a dihydroxy group that forms an amide or ester, respectively, with the groups X and Fl. Fl may include any suitable reporter species, such as a luminophore for luminescence assays or an isotope for radioassays. For example, Fl may include a fluorescein or rhodamine that forms a thiourea, ester, or amide bond with the group X. Preferred structures include 1,2 and 1,4-diaminocyclohexyl-linked tracers, as described in PCT Publication No. WO 00/75662, published December 14, 2000.

### Example 6

**[0070]** This example describes methods and kits for detecting phosphate modifications and/or associated enzymes and modulators in whole cells. The methods generally comprise growing cells under desired conditions, lysing the cells, incubating the cells before and/or after lysis with one or more reagents, and detecting the presence, quantity, and/or activity of species and/or reactions of interest. The kits generally comprise collections of reagents and/or other materials of interest, including substrates, binding partners, and/or lysis buffers, among others.

### Example 7

**[0071]** This example describes miscellaneous applications and other uses for the various assays described herein.

**[0072]** The applications include detecting any of the modifications, enzymes, and/or modulators identified herein. The modifications include cyclization and/or decyclization, as described above. The enzymes include cyclases and/or phosphodiesterases, including variants such as isoenzymes thereof. For example, the cyclases include adenylyl cyclase and guanylyl cyclase, among others, and the phosphodiesterases include PDE 1 through PDE 10, among others. The modulators include modulators of these enzymes, among others. For example, the cyclase modulators include forskolin and ODQ, among others, and the phosphodiesterase modulators include cilostamide, dipyridamole, EHNA hydrochloride, etazolate hydrochloride, MBCQ, MMPX, MY-5445, Ro 20-1724, rolipram, siguazodan, vinpocetine, and Zaprinast, among

others.

**[0073]** The applications also include combining assays for different modifications, enzymes, and/or modulators to form integrated assays, for example, by combining a phosphorylation assay and a cyclization assay to study signaling mechanisms involving multiple cell-signaling pathways.

#### **Example 8**

**[0074]** This example describes kits for use in performing assays. The kits may include substrates and/or binding partners for performing the assays described herein. These substrates and/or binding partners may include luminophores, quenchers, and/or energy transfer partners, among others. The kits also may include sample holders such as microplates or biochips that have been treated to act as binding partners. The kits optionally may include additional reagents, including but not limited to buffering agents, luminescence calibration standards, enzymes, enzyme substrates, nucleic acid stains, labeled antibodies, or other additional luminescence detection reagents. The substrates, binding partners, and/or additional reagents optionally are present in pure form, as concentrated stock solutions, or in prediluted solutions ready for use in the appropriate energy transfer assay. Typically, the kit is designed for use in an automated and/or high-throughput assay, and so is designed to be fully compatible with microplate readers, microfluidic methods, and/or other automated high-throughput methods.

#### **Example 9**

**[0075]** This example describes exemplary luminescence assays. Further aspects of these assays as well as additional luminescence assays and apparatus for performing luminescence assays are described in the following materials: U.S. Patent No. 6,097,025, issued September 24, 1998; and Joseph R. Lakowicz, Principles of Fluorescence Spectroscopy (2nd ed. 1999).

**[0076]** Luminescence, as defined above, is the emission of light from excited electronic states of atoms or molecules, including photoluminescence, chemiluminescence, and electrochemiluminescence, among others. Luminescence may be used in a variety of assays, including (A) intensity assays, (B) polarization assays, and (C) energy transfer assays, among others.

#### **A. Intensity Assays**

**[0077]** Luminescence intensity assays involve monitoring the intensity (or amount) of light emitted from a composition. The intensity of emitted light will depend on the extinction coefficient, quantum yield, and number of luminescent analytes in the composition, among others. These quantities, in turn, will depend on the environment of the analyte, among others, including the proximity and efficacy of quenchers and energy transfer partners. Thus, luminescence intensity assays may be used to study binding reactions, among other applications.

#### **B. Polarization Assays**

**[0078]** Luminescence polarization assays involve the absorption and emission of polarized light. Here, polarization refers to the direction of the light's electric field, which generally is perpendicular to the direction of the light's propagation. In a luminescence polarization assay, specific molecules within a composition are labeled with one or more luminophores. The composition then is illuminated with polarized excitation light, which preferentially excites luminophores having absorption dipoles aligned parallel to the polarization of the excitation light. These molecules subsequently decay by preferentially emitting light polarized parallel to their emission dipoles. The extent of polarization of the total emitted light depends on the extent of molecular reorientation during the time interval between luminescence excitation and emission, which is termed the luminescence lifetime,  $\tau$ . In turn, the extent of molecular reorientation depends on the luminescence lifetime and the size, shape, and environment of the reorienting molecule. Thus, luminescence polarization assays may be used to quantify binding reactions and enzymatic activity, among other applications. In particular, molecules commonly rotate (or "tumble") via diffusion, with a rotational correlation time  $\tau_{rot}$  that is proportional to their volume, or the cube of their radius of gyration. (This cubic dependence on radius makes polarization assays very sensitive to binding.) Thus, during their luminescence lifetime, relatively large molecules will not reorient significantly, so that their total luminescence will be relatively polarized. In contrast, during the same time interval, relatively small molecules will reorient significantly, so that their total luminescence will be relatively unpolarized.

**[0079]** The relationship between polarization and intensity is expressed by the following equation:

$$P = \frac{I_{\parallel} - I_{\perp}}{I_{\parallel} + I_{\perp}} \quad (1)$$

Here,  $P$  is the polarization,  $I_{\parallel}$  is the intensity of luminescence polarized parallel to the polarization of the excitation light, and  $I_{\perp}$  is the intensity of luminescence polarized perpendicular to the polarization of the excitation light.  $P$  generally varies from zero to one-half for randomly oriented molecules (and zero and one for aligned molecules). If there is little rotation between excitation and emission,  $I_{\parallel}$  will be relatively large,  $I_{\perp}$  will be relatively small, and  $P$  will be close to one-half. ( $P$  may be less than one-half even if there is no rotation; for example,  $P$  will be less than one-half if the absorption and emission dipoles are not parallel.) In contrast, if there is significant rotation between absorption and emission,  $I_{\parallel}$  will be comparable to  $I_{\perp}$ , and  $P$  will be close to zero. Polarization often is reported in milli- $P$  units ( $1000 \times P$ ), which for randomly oriented molecules will range between 0 and 500, because  $P$  will range between zero and one-half.

**[0080]** Polarization also may be described using other equivalent quantities, such as anisotropy. The relationship between anisotropy and intensity is expressed by the following equation:

$$r = \frac{I_{\parallel} - I_{\perp}}{I_{\parallel} + 2I_{\perp}} \quad (2)$$

Here,  $r$  is the anisotropy. Polarization and anisotropy include the same information, although anisotropy may be more simply expressed for systems containing more than one luminophore. In the description and paragraphs that follow, these terms may be used interchangeably, and a generic reference to one should be understood to imply a generic reference to the other.

**[0081]** The relationship between polarization and rotation is expressed by the Perrin equation:

$$\left( \frac{1}{P} - \frac{1}{3} \right) = \left( \frac{1}{P_0} - \frac{1}{3} \right) \cdot \left( 1 + \frac{\tau}{\tau_{rot}} \right) \quad (3)$$

Here,  $P_0$  is the polarization in the absence of molecular motion (intrinsic polarization),  $\tau$  is the luminescence lifetime (inverse decay rate) as described above, and  $\tau_{rot}$  is the rotational correlation time (inverse rotational rate) as described above.

**[0082]** The Perrin equation shows that luminescence polarization assays are most sensitive when the luminescence lifetime and the rotational correlation time are similar. Rotational correlation time is proportional to molecular weight, increasing by about 1 nanosecond for each 2,400 dalton increase in molecular weight (for a spherical molecule). For shorter lifetime luminophores, such as fluorescein, which has a luminescence lifetime of roughly 4 nanoseconds, luminescence polarization assays are most sensitive for molecular weights less than about 40,000 daltons. For longer lifetime probes, such as Ru(bpy)<sub>2</sub>dc bpy (ruthenium 2,2'-dibipyridyl 4,4'-dicarboxyl-2,2'-bipyridine), which has a lifetime of roughly 400 nanoseconds, luminescence polarization assays are most sensitive for molecular weights between about 70,000 daltons and 4,000,000 daltons.

**[0083]** Luminescence polarization assays may be used in a variety of formats. In one format, the concentration of an analyte in solution can be measured by supplying a labeled tracer that competes with the analyte for a binding moiety, particularly a binding moiety larger than the labeled tracer. In this "competitive" format, the concentration of the analyte is inversely correlated with the enhancement of luminescence polarization in the light emitted by the tracer when it competitively binds the common moiety. In another format, the concentration of a target can be measured by supplying a labeled tracer that is capable of binding the target. In this case, the enhancement of polarization is a direct measure of the concentration of target. The target further may be, for example, an activated receptor, where activation can be indirectly measured by the directly measured concentration of a generated molecule or by its binding to labeled tracer *per se*.

### C. Energy Transfer Assays

**[0084]** Energy transfer is the transfer of luminescence energy from a donor luminophore to an acceptor without emission by the donor. In energy transfer assays, a donor luminophore is excited from a ground state into an excited state by absorption of a photon. If the donor luminophore is sufficiently close to an acceptor, excited-state energy may be trans-



ferred from the donor to the acceptor, causing donor luminescence to decrease and acceptor luminescence to increase (if the acceptor is luminescent). The efficiency of this transfer is very sensitive to the separation  $R$  between donor and acceptor, decaying as  $1/R^6$ . Energy transfer assays use energy transfer to monitor the proximity of donor and acceptor, which in turn may be used to monitor the presence or activity of an analyte, among others.

**[0085]** Energy transfer assays may focus on an increase in energy transfer as donor and acceptor are brought into proximity. These assays may be used to monitor binding, as between two molecules  $X$  and  $Y$  to form a complex  $X : Y$ . Here, colon ( $:$ ) represents a noncovalent interaction. In these assays, one molecule is labeled with a donor  $D$ , and the other molecule is labeled with an acceptor  $A$ , such that the interaction between  $X$  and  $Y$  is not altered appreciably. Independently,  $D$  and  $A$  may be covalently attached to  $X$  and  $Y$ , or covalently attached to binding partners of  $X$  and  $Y$ .

**[0086]** Energy transfer assays also may focus on a decrease in energy transfer as donor and acceptor are separated. These assays may be used to monitor cleavage, as by hydrolytic digestion of doubly labeled substrates (peptides, nucleic acids). In one application, two portions of a polypeptide are labeled with  $D$  and  $A$ , so that cleavage of the polypeptide by a protease such as an endopeptidase will separate  $D$  and  $A$  and thereby reduce energy transfer. In another application, two portions of a nucleic acid are labeled with  $D$  and  $A$ , so that cleavage by a nuclease such as a restriction enzyme will separate  $D$  and  $A$  and thereby reduce energy transfer.

**[0087]** Energy transfer between  $D$  and  $A$  may be monitored in various ways. For example, energy transfer may be monitored by observing an energy-transfer induced decrease in the emission intensity of  $D$  and increase in the emission intensity of  $A$  (if  $A$  is a luminophore). Energy transfer also may be monitored by observing an energy-transfer induced decrease in the lifetime of  $D$  and increase in the apparent lifetime of  $A$ .

**[0088]** In a preferred mode, a long-lifetime luminophore is used as a donor, and a short-lifetime luminophore is used as an acceptor. Suitable long-lifetime luminophores include metal-ligand complexes containing ruthenium, osmium, etc., and lanthanide chelates containing europium, terbium, etc. In time-gated assays, the donor is excited using a flash of light having a wavelength near the excitation maximum of  $D$ . Next, there is a brief wait, so that electronic transients and/or short-lifetime background luminescence can decay. Finally, donor and/or acceptor luminescence intensity is detected and integrated. In frequency-domain assays, the donor is excited using time-modulated light, and the phase and/or modulation of the donor and/or acceptor emission is monitored relative to the phase and/or modulation of the excitation light. In both assays, donor luminescence is reduced if there is energy transfer, and acceptor luminescence is observed only if there is energy transfer.

### **Example 10**

**[0089]** This example shows assays with improved signals, signal-to-noise ratios, and/or signal-to-background ratios.

**[0090]** Signal may be enhanced in several ways, including (1) using a high color temperature light source, such as a xenon arc lamp, in a continuous illumination mode, (2) using a dichroic or multi-dichroic beamsplitter, and/or (3) using a sample holder whose shape is "matched" to the shape of the optical beam of the instrument, especially if the sample holder is elevated to bring the sample closer to a detector. The high color temperature light source increases the number of usable photons, which is important because the lower limit of the signal-to-noise ratio is set by the square root of the total number of photons collected in the measurement. These enhancements are described in more detail in the following U.S. Patent: Patent No. 6,297,018, issued February 10, 2001.

**[0091]** Signal-to-noise ratios can be enhanced at least in part by increasing signals, for example, by using the techniques described in the previous paragraph.

**[0092]** Signal-to-background ratios can be enhanced in several ways, including (1) using confocal optical systems having a sensed volume to avoid luminescence from the microplate walls, (2) selecting a microplate or other substrate that increases the signal and reduces the luminescent background from materials in the microplate, (3) selecting the light sources, luminescence filters, optics, signal collection electronics, and mechanical system used in the luminescence detection optical system for maximum signal-to-background ratio, and (4) utilizing signal processing, background subtraction, and luminescence lifetime techniques, particularly FLAME™ methodology for background reduction, as described below. These enhancements are described in more detail in the following U.S. patent and U.S. patent application Patent No. 6,071,748, issued April 17, 1998; Patent No. 6,297,018, issued February 10, 2001.

### **Example 16**

**[0093]** This example shows mechanisms for increasing the change in polarization that accompanies a change in binding, so that the change in binding can be measured more easily. These mechanisms may be used in any of the assays described here involving luminescently labeled species, such as labeled cyclic nucleotides and labeled nonhydrolyzable GTP analogs, among others.

**[0094]** The change in polarization upon binding can be increased by making any linker between the luminophore and the labeled species (e.g., the cyclic nucleotide or GTP analog) as short and/or rigid as possible, while maintaining relevant

substrate properties for the enzymes involved in the assay. Short and/or rigid linkers will restrict luminophore motion relative to the labeled species, reducing the "propeller effect" so that the luminophore more accurately reports the motion of both the free and bound labeled species. The rigidity of the linker may be increased by avoiding using hexanoic acid linkers, which typically are long and flexible, and by using cyclic linkers and amide groups in place of methylene groups, among other mechanisms.

**[0095]** The change in polarization upon binding also can be increased by including an appropriately positioned energy transfer acceptor on the binding partner, so that energy transfer will occur from the luminophore to the acceptor upon incorporation. Such energy transfer will shorten the lifetime of the luminophore, thereby increasing its polarization (because polarization varies inversely with lifetime, all else being equal).

**[0096]** The change in polarization upon binding also can be increased by decreasing the mobility of the binding partner for the labeled species. Mobility can be decreased by increasing the size of the binding partner, either directly or by forming a complex with a mass label. Suitable mass labels include other molecules and beads, among others. Mobility also can be decreased by attaching the binding partner to a surface, such as the surface of a sample holder. Attachment to other molecules, beads, and/or surfaces may be accomplished using any of a number of well-known reactive groups.

**[0097]** The assays provided by the invention may have advantages over prior assays for detecting molecular modifications. The existence and/or identity of these advantages will depend on such as (but not always requiring) one or more of the following. First, they may be used without radioactivity. Second, they may be homogenous, so that they do not require physical separation steps or wash steps. Third, they may have stable endpoints, so that results are relatively insensitive to the timing of any measurement or detection steps. Fourth, they may be sensitive, so that picomolar amounts of cyclic nucleotides may be detected. Fifth, they may be used with solution and cell-based samples.

## Claims

1. A method of assaying cyclization or decyclization of a nucleotide in a sample, comprising: contacting a nucleotide with a binding partner that binds specifically to cyclized nucleotide or to noncyclized nucleotide, but not both; and detecting a response indicative of binding, or of the extent of binding, between the cyclized or noncyclized nucleotide and the binding partner, **characterised in that** the binding partner includes a metal ion that is required for binding between the binding partner and the cyclized or noncyclized nucleotide.

2. The method of claim 1, where the step of detecting a response comprises:

exposing the sample to a condition capable of inducing luminescence from the sample; and measuring a detectable luminescence response, where the detectable luminescence response is indicative of the extent of binding between the cyclized or noncyclized nucleotide and the binding partner.

3. The method of claim 2, where the cyclized nucleotide, the noncyclized nucleotide, or both are luminescent.

4. A method of any preceding claim which is a method of assaying the activity of an enzyme that cyclizes or decyclizes the nucleotide, further comprising:

contacting the nucleotide with the enzyme; and correlating the response with the activity of the enzyme.

5. The method of claim 4, where the enzyme is selected from the group consisting of cyclases and phosphodiesterases.

6. The method of claim 4 or claim 5, further comprising:

contacting the nucleotide and enzyme with a candidate compound; and determining the ability of the candidate compound to enhance or inhibit nucleotide cyclization or decyclization by its effect on the response.

7. The method of any preceding claim, where the metal ion is a tricationic metal ion.

8. The method of claim 7, where the tricationic metal ion is  $\text{Ga}^{3+}$ .

9. The method of any preceding claim, where the assay is a luminescence intensity assay, a luminescence polarization assay, or a luminescence resonance energy transfer assay.

10. The method of any preceding claim, where the binding partner further includes a macromolecule or a nanoparticle.
11. The method of any preceding claim, where the binding partner further includes a quencher or an energy transfer partner.
12. The method of any preceding claim, where the specific binding is **characterized by** a binding coefficient of no larger than about  $10^{-8}$  M.
13. The method of any preceding claim, further comprising:
  - providing a sample holder having a plurality of sample sites supporting a corresponding plurality of samples; and
  - repeating the steps of contacting and detecting for the plurality of samples.
14. The method of any preceding claim, where the step of detecting a response is performed without separating bound nucleotide from unbound nucleotide.

#### Patentansprüche

1. Verfahren zum Untersuchen der Cyclisierung oder Decyclisierung eines Nukleotids in einer Probe, wobei das Verfahren folgendes umfasst: das Inkontaktbringen eines Nukleotids mit einem Bindungspartner, der speziell an cyclisierte Nukleotide oder an nicht-cyclisierte Nukleotide bindet, jedoch nicht an beide; und das Detektieren einer Reaktion, welche die Bindung oder das Ausmaß der Bindung zwischen dem cyclisierten oder nicht-cyclisierten Nukleotid und dem Bindungspartner anzeigt, **dadurch gekennzeichnet, dass** der Bindungspartner ein Metallion aufweist, das für die Bindung zwischen dem Bindungspartner und dem cyclisierten oder nicht-cyclisierten Nukleotid erforderlich ist.
2. Verfahren nach Anspruch 1, wobei der Schritt des Detektierens einer Reaktion folgendes umfasst:
  - das Aussetzen der Probe einem Zustand, der eine Lumineszenz von der Probe induzieren kann; und
  - das Messen einer erkennbaren Lumineszenzreaktion, wobei die erkennbare Lumineszenzreaktion das Ausmaß der Bindung zwischen dem cyclisierten und dem nicht-cyclisierten Nukleotid und dem Bindungspartner anzeigt.
3. Verfahren nach Anspruch 2, wobei das cyclisierte Nukleotid, das nicht-cyclisierte Nukleotid oder beide lumineszierend sind.
4. Verfahren nach einem der vorstehenden Ansprüche, wobei es sich dabei um ein Verfahren zum Untersuchen der Aktivität eines Enzyms handelt, welches das Nukleotid cyclisiert oder decyclisiert, wobei das Verfahren ferner folgendes umfasst:
  - das Inkontaktbringen des Nukleotids mit dem Enzym; und
  - das Korrelieren der Reaktion mit der Aktivität des Enzyms.
5. Verfahren nach Anspruch 4, wobei das Enzym ausgewählt wird aus der Gruppe, die Zyklasen und Phosphodiesterasen umfasst.
6. Verfahren nach Anspruch 4 oder 5, wobei dieses ferner folgendes umfasst:
  - das Inkontaktbringen des Nukleotids und des Enzyms mit einem Wirkstoffkandidaten; und
  - das Bestimmen der Fähigkeit des Wirkstoffkandidaten, die Nukleotid-Cyclisierung oder -Decyclisierung durch dessen Effekt auf die Reaktion zu fördern oder zu hemmen.
7. Verfahren nach einem der vorstehenden Ansprüche, wobei es sich bei dem Metallion um ein trikationisches Metallion handelt.
8. Verfahren nach Anspruch 7, wobei es sich bei dem trikationischen Metallion um  $Ga^{3+}$  handelt.
9. Verfahren nach einem der vorstehenden Ansprüche, wobei es sich bei der Probe um eine Lumineszenzintensitäts-

Probe, eine Lumineszenzpolarisierungs-Probe oder eine Probe der Lumineszenzresonanzenergieübertragung handelt.

10. Verfahren nach einem der vorstehenden Ansprüche, wobei der Bindungspartner ferner ein Makromolekül oder ein Nanopartikel aufweist.

11. Verfahren nach einem der vorstehenden Ansprüche, wobei der Bindungspartner ferner einen Quencher oder einen Energieübertragungspartner handelt.

12. Verfahren nach einem der vorstehenden Ansprüche, wobei die spezifische Bindung durch einen Bindungskoeffizienten gekennzeichnet ist, der nicht größer ist als etwa  $10^{-8}$  M.

13. Verfahren nach einem der vorstehenden Ansprüche, wobei dieses ferner folgendes umfasst:

das Bereitstellen eines Probenhalters mit einer Mehrzahl von Probenstellen, die eine entsprechende Mehrzahl von Proben tragen; und  
das Wiederholen die Schritte des Inkontaktbringens und des Detektierens für die Mehrzahl von Proben wiederholt werden.

14. Verfahren nach einem der vorstehenden Ansprüche, wobei der Schritt des Detektierens einer Reaktion ausgeführt wird, ohne das gebundene Nukleotid von dem ungebundenen Nukleotid zu trennen.

## Revendications

1. Procédé d'analyse d'une cyclisation ou décyclisation d'un nucléotide dans un échantillon, comprenant les étapes consistant à : mettre en contact un nucléotide avec un partenaire de liaison qui se lie spécifiquement à un nucléotide cyclisé ou à un nucléotide non cyclisé, mais pas aux deux ; et détecter une réponse indicative de la liaison, ou de l'étendue de la liaison, entre le nucléotide cyclisé ou non cyclisé et le partenaire de liaison, **caractérisé en ce que** le partenaire de liaison comprend un ion métallique qui est nécessaire pour la liaison entre le partenaire de liaison et le nucléotide cyclisé ou non cyclisé.

2. Procédé selon la revendication 1, dans lequel la détection d'une réponse comprend les étapes consistant à :

exposer l'échantillon à une condition capable d'induire une luminescence de l'échantillon ;  
mesurer une réponse de luminescence détectable, dans lequel la réponse de luminescence détectable est indicative de l'étendue de la liaison entre le nucléotide cyclisé ou non cyclisé et le partenaire de liaison.

3. Procédé selon la revendication 2, dans lequel le nucléotide cyclisé, le nucléotide non cyclisé, ou les deux sont luminescents.

4. Procédé selon l'une quelconque des revendications précédentes, qui est un procédé d'analyse de l'activité d'une enzyme qui cyclise ou décyclise le nucléotide, comprenant en outre les étapes consistant à :

mettre en contact le nucléotide avec l'enzyme ; et  
corrélér la réponse avec l'activité de l'enzyme.

5. Procédé selon la revendication 4, dans lequel l'enzyme est choisie dans le groupe constitué de cyclases et de phosphodiésterases.

6. Procédé selon la revendication 4 ou 5, comprenant en outre les étapes consistant à :

mettre en contact le nucléotide et l'enzyme avec un composé candidat ; et  
déterminer la capacité du composé candidat à améliorer ou inhiber la cyclisation ou décyclisation du nucléotide par son effet sur la réponse.

7. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'ion métallique est un ion métallique tricationique.

8. Procédé selon la revendication 7, dans lequel l'ion métallique tricationique est  $Ga^{3+}$ .
9. Procédé selon l'une quelconque des revendications précédentes, dans lequel l'analyse est une analyse d'intensité de luminescence, une analyse de polarisation de luminescence, ou une analyse de transfert d'énergie de résonance de luminescence.
10. Procédé selon l'une quelconque des revendications précédentes, dans lequel le partenaire de liaison comprend en outre une macromolécule ou une nanoparticule.
11. Procédé selon l'une quelconque des revendications précédentes, dans lequel le partenaire de liaison comprend en outre un extincteur ou un partenaire de transfert d'énergie.
12. Procédé selon l'une quelconque des revendications précédentes, dans lequel la liaison spécifique est **caractérisée par** un coefficient de liaison de pas plus d'environ  $10^{-8}$  M.
13. Procédé selon l'une quelconque des revendications précédentes, comprenant en outre les étapes consistant à :  
fournir un porte-échantillon ayant une pluralité de sites d'échantillon supportant une pluralité correspondante d'échantillons ; et  
répéter les étapes de mise en contact et de détection pour la pluralité d'échantillons.
14. Procédé selon l'une quelconque des revendications précédentes, dans lequel la détection d'une réponse est effectuée sans séparer le nucléotide lié du nucléotide non lié.




**Fig. 1****Fig. 2****G-PROTEIN-LINKED RECEPTOR MECHANISM****Fig. 3****ENZYME-LINKED RECEPTOR MECHANISM**

Fig. 4

## INTRACELLULAR SIGNALING PATHWAYS




Fig. 5






Fig. 6




Fig. 7




Fig.




Fig.

9




Fig.

10




Fig.




Fig.




Fig. 13





Fig. 14



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

### Patent documents cited in the description

- US 9903678 W [0042]
- WO 99042817 A [0042]
- WO 0075662 A [0069]
- US 6097025 A [0075]
- US 6297018 B [0090] [0092]
- US 6071748 A [0092]

### Non-patent literature cited in the description

- **BOB SINCLAIR.** Everything's Great When It Sits on a Chip: A Bright Future for DNA Arrays. *THE SCIENTIST*, 24 May 1999, vol. 13, 18 [0042]
- **JOSEPH R. LAKOWICZ.** Principles of Fluorescence Spectroscopy. 1999 [0044] [0075]
- **RICHARD P. HAUGLAND.** Handbook of Fluorescent Probes and Research Chemicals. 1996 [0045]

专利名称(译)	分子修饰测定		
公开(公告)号	<a href="#">EP2012125B1</a>	公开(公告)日	2013-01-23
申请号	EP2008166032	申请日	2001-04-30
[标]申请(专利权)人(译)	MDS分析TECH美国		
申请(专利权)人(译)	MDS分析技术 ( US ) INC.		
当前申请(专利权)人(译)	分子器件 , LLC		
[标]发明人	HUANG WEI SPORTSMAN J RICHARD TERPETSCHNIG EWALD A HOEKSTRA MERL E		
发明人	HUANG, WEI SPORTSMAN, J. RICHARD TERPETSCHNIG, EWALD A. HOEKSTRA, MERL E.		
IPC分类号	G01N33/58 G01N33/02 C07K7/06 C07K7/08 B01L3/00 C12Q1/48 G01N33/53 G01N33/542 G01N33/566 G01N35/00 G01N35/02 G01N35/04 G01N35/10		
CPC分类号	C07K7/06 B01L3/50853 C07K7/08 C12Q1/485 G01N33/5308 G01N33/542 G01N33/566 G01N33/582 G01N35/028 G01N35/1011 G01N35/1074 G01N2035/00237 G01N2035/0405 G01N2035/0425 G01N2333/9121 Y10S436/80 Y10S436/805		
代理机构(译)	HARRISON GODDARD FOOTE		
优先权	PCT/US2000/016025 2000-06-09 WO 09/596444 2000-06-19 US 60/223642 2000-08-08 US 09/844655 2001-04-27 US 60/200594 2000-04-28 US 60/241032 2000-10-17 US		
其他公开文献	EP2012125A1		
外部链接	<a href="#">Espacenet</a>		

## 摘要(译)

一种测定方法，包括：使样品与结合配偶体接触，所述结合配偶体特异性结合第一底物分子，所述第一底物分子可以在样品中但不与第二底物分子结合，所述第二底物分子可以在样品中；检测指示第一底物和结合配偶体之间结合或结合程度的反应，其特征在于结合配偶体包括结合配偶体与底物或产物之间结合所需的金属离子和在不将结合的第一基板与未结合的第一基板分离的情况下执行响应检测。

